Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

scientific article published on 16 November 2017

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DIABET.2017.10.001
P698PubMed publication ID29153485

P2093author name stringW Schmider
J Pettus
G B Bolli
R Roussel
T S Bailey
O Klein
R Dahmen
M Maroccia
N Nassr
P921main subjecttype-1 diabetesQ124407
pharmacokineticsQ323936
insulin glargineQ417317
pharmacodynamicsQ725307
P577publication date2017-11-16
P1433published inDiabetes and MetabolismQ15758385
P1476titleMorning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

Reverse relations

cites work (P2860)
Q92545478Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
Q92787063Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
Q89230569Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study
Q92566991Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019
Q89494400Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study
Q92348737Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy)
Q91750614Considering Blood Dilution improves the Precision of Continuous Whole Blood Glucose Measurements
Q92721967Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different
Q57809857Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2)
Q93034237Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)
Q89273744Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles
Q92100367Glargine-300: An updated literature review on randomized controlled trials and real-world studies
Q92304196Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care
Q57288400Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
Q89990683In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
Q89887235InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Q92550113Insulin Initiation and Titration in Patients With Type 2 Diabetes
Q92417832Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Q52611423Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.
Q92116334Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues
Q89475403Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site
Q90684268Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
Q92956760Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Q90402553Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons

Search more.